期刊文献+

奥沙利铂联合卡培他滨治疗晚期大肠癌35例 被引量:4

Efficacy of Oxaliplatin combined with Capecitabine therapy for advanced colorectal cancer
暂未订购
导出
摘要 目的观察奥沙利铂联合卡培他滨治疗晚期大肠癌的临床疗效及毒副反应。方法我院2008年1月~2009年6月共收治35例晚期大肠癌患者,均采用奥沙利铂联合卡培他滨治疗,具体为:奥沙利铂130 mg/m2,ivgtt 2h,d1;卡培他滨1250 mg/m2,po,bid,d1~14,21d为1个周期。结果 35例患者均可进行疗效评价,CR 3例(8.6%),PR 17例(48.6%),SD 13例(37.1%),PD 2例(5.7%),总有效率(CR+PR)为57.2%,中位OS 19.2个月,中位PFS 8.1个月。主要的毒副反应为消化道反应、血液毒性、神经毒性、手足综合征等,经对症处理后患者均能耐受。结论奥沙利铂联合卡培他滨治疗晚期大肠癌疗效显著,毒副反应小,耐受性好,是值得临床推广应用的姑息化疗方案。 Objective To observe the efficacy and toxicity of oxaliplatin combined capecitabine therapy for advanced colorectal cancer. Methods All of 35 advanced eolorectal cancer patients were treated by oxaliplatin combined capeeitabine, Oxaliplatin injection of 130 mg/m2 was given to the patients on the first day, and capecitabine per os of 1 250 mg/m2 twice a day was given to the patients from 1st to 14th days, 21 days for a cycle. Results All of 35 cases were evaluable for efficacy. There were 3 complete response(CR), 17 patial response(PR), 13 stable disease(SD) and 2 progress dlsease(PD). The total efficacy was 57.2%, median overall survival(OS) was 19.2 months, and median progression-free survival(PFS) was 8.1 months. The most common toxicities were gastrointestinal reactions, blood toxicity, neurotoxicity, hand-foot syndrome, but all of them could be tolerable after appropriate treatment. Conclusion Oxaliplatin combined with capecitabine was an effective and well tolerated palliative chemotherapy regimen in the treatment of advanced eolorectal cancer and the toxicity was small. It was worth of further clinical research.
出处 《中国现代医生》 2012年第10期129-130,132,共3页 China Modern Doctor
关键词 奥沙利铂 卡培他滨 毒副反应 晚期大肠癌 Oxaliplatin Capecitabine Toxicity Advanced colorectal cancer
  • 相关文献

参考文献8

二级参考文献32

  • 1谭立新,杨玲,李沛霖,李扬.国产奥沙利铂联合亚叶酸钙和氟尿嘧啶治疗晚期胃癌的临床研究[J].临床肿瘤学杂志,2005,10(2):169-171. 被引量:9
  • 2秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:269
  • 3金懋林.进展期胃癌全身化学治疗研究新进展[J].癌症进展,2007,5(1):18-24. 被引量:82
  • 4De Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and 5 fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol, 1988, 24: 1499- 1503.
  • 5QUASAR Collaborative Group.Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as an adjuvant chemotherapy for colorectal cancer: a randomized trial. Lancet, 2000, 356:1276.
  • 6Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin ) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer, 2006, 94 : 969-975.
  • 7Macdonald JS. Adjuvant therapy of colon cancer. Ca Cancer J Clin, 1999, 49:202-219.
  • 8Haydon A. Adjuvant chemotherapy in colon cancer: what is the evidence? Intern Med J, 2003, 33:119-124.
  • 9Saris CP, Van de Vaart PJ, Rietbroek RC, et al. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis, 1996, 17:2763-2769.
  • 10Cassidy J, Tabemero J, Twelves C, et al. XELOX ( capecitabine plus oxaliplatin ): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004, 22:2084-2091.

共引文献69

同被引文献20

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部